NASDAQ:MGRX Mangoceuticals (MGRX) Stock Price, News & Analysis → This military-backed stock “owns” AI market (From Porter & Company) (Ad) Free MGRX Stock Alerts $0.39 -0.02 (-4.84%) (As of 05/31/2024 ET) Add Compare Share Share Today's Range$0.38▼$0.4250-Day Range$0.19▼$0.5252-Week Range$0.14▼$2.38Volume545,763 shsAverage Volume14.29 million shsMarket Capitalization$9.77 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Mangoceuticals alerts: Email Address Ad Crypto 101 MediaShocking $16T Elon Musk Crypto LeakReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.Click here now to get your copy. About Mangoceuticals Stock (NASDAQ:MGRX)Mangoceuticals, Inc. develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.Read More MGRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MGRX Stock News HeadlinesMay 29 at 7:00 AM | americanbankingnews.comMangoceuticals, Inc. (NASDAQ:MGRX) Short Interest UpdateMay 28, 2024 | globenewswire.comMangoceuticals, Inc. Announces Completion of First Batch of Mango ED Products for Marketing and Distribution in Mexico and Latin American MarketsMay 23, 2024 | globenewswire.comMangoRx Engages Renown International Digital and Performance Marketing Company Crakmedia to Champion its Digital Marketing EffortsMay 23, 2024 | investorplace.comMove Over Ozempic! 3 New GLP-1 Drugs and Products Coming Soon.May 21, 2024 | investorplace.comWhy Is Mangoceuticals (MGRX) Stock Up 130% Today?May 21, 2024 | finanznachrichten.deMangoceuticals, Inc.: MangoRx to Introduce Oral Semaglutide and Tirzepatide in Response to Increasing Patient Demand for GLP-1 MedicationsMay 21, 2024 | msn.comMangoceuticals Develops Oral GLP-1s: Stock SoarsMay 21, 2024 | globenewswire.comMangoRx to Introduce Oral Semaglutide and Tirzepatide in Response to Increasing Patient Demand for GLP-1 MedicationsMay 17, 2024 | finanznachrichten.deMangoceuticals, Inc.: MangoRx Reports Revenue Growth of 108% in Q1 2024 Fueled by Amplified Customer Acquisition and Early Market PenetrationMay 16, 2024 | investorplace.comMGRX Stock Earnings: Mangoceuticals Reported Results for Q1 2024May 16, 2024 | globenewswire.comMangoRx Reports Revenue Growth of 108% in Q1 2024 Fueled by Amplified Customer Acquisition and Early Market PenetrationMay 2, 2024 | finance.yahoo.comMangoceuticals Granted 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement and Conditional Approval of Compliance with Nasdaq’s Minimum Stockholders’ Equity RequirementMay 2, 2024 | globenewswire.comMangoceuticals Granted 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement and Conditional Approval of Compliance with Nasdaq's Minimum Stockholders' Equity RequirementApril 25, 2024 | finance.yahoo.comMangoceuticals Acquires Global Patent Portfolio to Revolutionize Preventive CareApril 13, 2024 | investing.comMangoceuticals partners with Emifarma for ED product developmentApril 12, 2024 | globenewswire.comMangoceuticals Subsidiary, MangoRx Mexico, Executes Technical Agreement with Mexican Pharmaceutical Manufacturer for Initial Development and Production of its Mango Erectile Dysfunction (ED) ProductsApril 10, 2024 | finance.yahoo.comThis Mangoceuticals Insider Increased Their Holding In The Last YearMarch 12, 2024 | finance.yahoo.comMangoRx Officially Launches ‘PRIME’ by MangoRx, Powered by Kyzatrex®️ FDA Approved Oral Testosterone Replacement Therapy (TRT) TreatmentMarch 12, 2024 | globenewswire.comMangoRx Officially Launches ‘PRIME' by MangoRx, Powered by Kyzatrex®️ FDA Approved Oral Testosterone Replacement Therapy (TRT) TreatmentFebruary 27, 2024 | benzinga.comMangoceuticals Stock (NASDAQ:MGRX), Quotes and News SummaryFebruary 20, 2024 | finance.yahoo.comMangoRx Launches Direct-To-Clinics Sales Division to Drive and Fuel Customer Acquisition and Revenue GrowthFebruary 20, 2024 | globenewswire.comMangoRx Launches Direct-To-Clinics Sales Division to Drive and Fuel Customer Acquisition and Revenue GrowthFebruary 13, 2024 | finance.yahoo.comMangoceuticals, Inc. (MGRX)February 13, 2024 | finance.yahoo.comMANGORX AWARDS SAN FRANCISCO TEAM FREE MANGORX ED PRODUCTS FOR ONE YEAR FOLLOWING BIG GAME LOSS TO KANSAS CITYFebruary 8, 2024 | msn.comWhy Compass Minerals International Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Thursday's Mid-Day SessionSee More Headlines Receive MGRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mangoceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/01/2024Today6/01/2024Next Earnings (Estimated)7/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Miscellaneous health & allied services, not elsewhere classified Sub-IndustryN/A Current SymbolNASDAQ:MGRX CUSIPN/A CIK1938046 Webwww.mangorx.com Phone833-626-4679FaxN/AEmployees3Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-9,210,000.00 Net Margins-1,068.72% Pretax Margin-1,068.60% Return on Equity-864.10% Return on Assets-577.68% Debt Debt-to-Equity RatioN/A Current Ratio0.07 Quick Ratio0.06 Sales & Book Value Annual Sales$730,000.00 Price / Sales13.38 Cash FlowN/A Price / Cash FlowN/A Book Value($0.04) per share Price / Book-9.84Miscellaneous Outstanding Shares24,820,000Free Float15,065,000Market Cap$9.77 million OptionableNot Optionable Beta1.27 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Eugene M. Johnston (Age 60)Chief Financial Officer Comp: $14kMs. Amanda Elizabeth Hammer (Age 38)Chief Operating Officer Comp: $105.42kKey CompetitorsOntrakNASDAQ:OTRKMarpaiNASDAQ:MRAIBioRestorative TherapiesNASDAQ:BRTXGreenbrook TMSNASDAQ:GBNHFDaVitaNYSE:DVAView All Competitors MGRX Stock Analysis - Frequently Asked Questions How have MGRX shares performed in 2024? Mangoceuticals' stock was trading at $0.2769 on January 1st, 2024. Since then, MGRX shares have increased by 42.1% and is now trading at $0.3936. View the best growth stocks for 2024 here. Are investors shorting Mangoceuticals? Mangoceuticals saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 27,100 shares, a decrease of 40.7% from the April 30th total of 45,700 shares. Based on an average daily trading volume, of 4,820,000 shares, the short-interest ratio is currently 0.0 days. Currently, 0.2% of the company's shares are sold short. View Mangoceuticals' Short Interest. When is Mangoceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, July 1st 2024. View our MGRX earnings forecast. How were Mangoceuticals' earnings last quarter? Mangoceuticals, Inc. (NASDAQ:MGRX) announced its earnings results on Monday, April, 1st. The company reported ($0.13) EPS for the quarter. The business earned $0.24 million during the quarter. Mangoceuticals had a negative trailing twelve-month return on equity of 864.10% and a negative net margin of 1,068.72%. When did Mangoceuticals IPO? Mangoceuticals (MGRX) raised $5 million in an initial public offering on Tuesday, March 21st 2023. The company issued 1,300,000 shares at $4.00 per share. Boustead Securities served as the underwriter for the IPO. How do I buy shares of Mangoceuticals? Shares of MGRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MGRX) was last updated on 6/1/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProDems have chosen Biden replacement?Paradigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceNvidia is about to pass AppleWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mangoceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
